- Advaxis is submitting an INDA to the FDA for phase I/II study of ADVX-HPV and MedImmune's MED14736 (both immunotherapy cancer drugs) to study the monotherapy effect of ADVX-HPV and the combined effect of both drugs on HPV-associated head/neck/cervical cancers.
- ADVX is an Lm-LLO-based immunotherapy and MED14736 is a checkpoint inhibitor.
- Although the rate of head and neck cancers not related to human papillomavirus (HPV) is declining, the rate of HPV-related head and neck cancers has skyrocketed. There are now approximately 12,000 new cases in the U.S. each year, and 400,000 worldwide.
Cancer immunotherapy is taking on one target after another, and Advaxis is determined to take on another challenging target by addressing HPV-related head and neck cancers and HPV-related cervical cancer.
It matters, because although there is now a vaccine against high-risk strains of HPV, only one third of young women have been vaccinated and approximately 20 million women are already infected.